Cathy Rude

Cooley advised Abivax, a clinical-stage biotech company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, on its $235.8 million initial public offering.

Cooley advised Turnstone Biologics, a clinical-stage biotechnology company, on its upsized $80 million initial public offering.

Cooley advised CinCor Pharma on its upsized $212 million initial public offering of 13,290,813 shares of common stock, which included a partial exercise of the underwriter’s option to purchase additional shares of common stock. CinCor, whose shares now trade on the Nasdaq Global Market under the symbol CINC, is a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases. CinCor’s IPO was one of the first IPOs of 2022. Partners Ryan Sansom, Div Gupta and Courtney Thorne led the Cooley team.

Cooley advised customer engagement platform Braze on its $572 million initial public offering of 8,800,000 shares of Class A common stock, which now trade on the Nasdaq Global Select Market under the symbol BRZE. Lawyers Nicole Brookshire, Jodie Bourdet, Peter Byrne and Owen Williams led the team advising Braze.

Cooley advised Vision Ridge, an alternative asset manager focused on sustainable real assets, on the closing of its third sustainable asset fund at $1.25 billion. Initially targeted at $1 billion of commitments, Sustainable Asset Fund III drew interest beyond the $1.25 billion hard cap. Partners Aaron Velli and Luke Bagley led the Cooley team advising Vision Ridge.